R&D Systems™ CHIR 99021

CHIR 99021 is a potent and highly selective inhibitor of glycogen synthase kinase 3 (GSK-3) (IC50 values are 6.7 and 10 nM for GSK-3β and GSK-3α respectively). Acts as Wnt activator. Exhibits >500-fold selectivity for GSK-3 over closely related kinases; also displays >800-fold selectivity against 45 additional enzymes and receptors. In combination with the irreversible inhibitor of LSD1 (Cat. No. 3852), CHIR 99021 enables reprogramming of mouse embryonic fibroblasts, transduced by Oct4 and Klf4 only, into iPSCs. Enhances mouse and human ESC self-renewal when used in combination with PD 0325901 (Cat. No. 4192). It promotes differentiation of hPSCs in cardiomyocytes and allows formation of extended pluripotent stem (EPS) cells in combination with (S)-(+)-Dimethindene maleate (Cat. No. 1425), tetracycline antibiotic (Cat. No. 3268) and human leukemia inhibitory factor. CHIR 99021 synthesized to cGMP guidelines also available. For more information on how to use CHIR 99021, see our protocols: Transdifferentiating Fibroblasts into Neurons, Culturing Transcriptomically Distinct Pluripotent mESCs, Converting Fibroblasts into Cardiomyocytes (9C Cocktail), Human iPSC-derived Myoblasts .